A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Multiple sclerosis (MS) is a CNS neurodegenerative disease requiring minimally invasive biomarkers for diagnosis and treatment monitoring.
• Differentially methylated circulating-free DNA (cfDNA) presents a promising avenue for disease biomarker development.
• Understanding oligodendrocyte death is crucial for MS pathogenesis and therapeutic strategies.

Purpose of the Study:

• To investigate demethylated myelin oligodendrocyte glycoprotein (MOG) cfDNA as a potential biomarker for oligodendrocyte death in MS.
• To assess the utility of MOG cfDNA methylation patterns in distinguishing active MS from inactive disease and healthy controls.

Main Methods:

• Quantitative real-time PCR and methylation-specific primers were employed to analyze MOG gene methylation patterns.
• MOG cfDNA methylation was studied in mouse models of demyelination and in human oligodendrocyte precursor cells (OPCs).
• Serum cfDNA was analyzed from patients with relapsing-remitting MS (RRMS) and healthy controls.

Main Results:

• Demethylated MOG cfDNA was observed in oligodendrocytes (ODCs) and increased in the serum of mice during demyelination, correlating with ODC death.
• Patients with active RRMS exhibited significantly higher levels of demethylated MOG cfDNA compared to those with inactive disease and healthy individuals.
• These findings highlight demethylated MOG cfDNA as a specific indicator of ODC death.

Conclusions:

• Demethylated MOG cfDNA serves as a minimally invasive biomarker for quantifying oligodendrocyte death in MS patients.
• This biomarker has the potential for monitoring disease activity and progression in multiple sclerosis.
• The study establishes a novel blood-based assay for assessing CNS damage in MS.